Elicio Therapeutics, Inc.

DB:9HA Stock Report

Market Cap: €53.1m

Elicio Therapeutics Management

Management criteria checks 3/4

Elicio Therapeutics' CEO is Bob Connelly, appointed in Oct 2018, has a tenure of 6.25 years. total yearly compensation is $678.30K, comprised of 73.5% salary and 26.5% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth €231.28K. The average tenure of the management team and the board of directors is 3.5 years and 3.3 years respectively.

Key information

Bob Connelly

Chief executive officer

US$678.3k

Total compensation

CEO salary percentage73.5%
CEO tenure6.3yrs
CEO ownership0.4%
Management average tenure3.5yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bob Connelly's remuneration changed compared to Elicio Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$47m

Jun 30 2024n/an/a

-US$39m

Mar 31 2024n/an/a

-US$39m

Dec 31 2023US$678kUS$499k

-US$35m

Sep 30 2023n/an/a

-US$33m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$475k

-US$28m

Sep 30 2022n/an/a

-US$28m

Mar 31 2022n/an/a

-US$27m

Dec 31 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$872kUS$450k

-US$16m

Compensation vs Market: Bob's total compensation ($USD678.30K) is above average for companies of similar size in the German market ($USD465.04K).

Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.

CEO

Bob Connelly (64 yo)

6.3yrs

Tenure

US$678,300

Compensation

Mr. Robert T. Connelly, also known as Bob, has been Chief Executive Officer and Director of Elicio Therapeutics Inc. since October 2018 and serves as its President and has been its Principal Accounting Off...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Connelly
CEO, President6.3yrsUS$678.30k0.44%
€ 231.3k
Christopher Haqq
Executive VP5.3yrsUS$673.82k0.30%
€ 157.5k
Darrell Irvine
Co-Founderno datano datano data
Michael DiVecchia
Senior Vice President of Operations & Human Resources5yrsno datano data
Peter DeMuth
Chief Scientific Officer3yrsno data0.0035%
€ 1.9k
Megan Filoon
General Counsel2yrsno datano data
Esther Welkowsky
Senior Vice President of Clinical Development4yrsno datano data
Joy Seymour
VP & Head of Regulatory Affairs2.7yrsno datano data
Thian Kheoh
Senior Vice President of Biometrics2yrsno datano data

3.5yrs

Average Tenure

58yo

Average Age

Experienced Management: 9HA's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Connelly
CEO, President6.3yrsUS$678.30k0.44%
€ 231.3k
Darrell Irvine
Co-Founderno datano datano data
Julian Adams
Independent Chairman & Member of Scientific Advisory Board8yrsUS$96.05k0%
€ 0
Karen Wilson
Independent Director1.6yrsUS$101.02k0.017%
€ 9.2k
Robert Richard Ruffolo
Independent Director & Member of Scientific Advisory Board7yrsUS$63.26k0%
€ 0
Adrian Bot
Member of Scientific Advisory Boardno datano datano data
Jay Venkatesan
Director1.6yrsUS$2.43m1.68%
€ 889.0k
Carol Ashe
Independent Director4.4yrsUS$71.59k0%
€ 0
Emanuele Ostuni
Member of Scientific Advisory Boardno datano datano data
Yekaterina Chudnovsky
Director2.3yrsUS$48.68k17.78%
€ 9.4m
Allen Nissenson
Independent Director1.6yrsUS$91.22k0%
€ 0
Pashtoon Kasi
Member of Scientific Advisory Boardno datano datano data

3.3yrs

Average Tenure

65yo

Average Age

Experienced Board: 9HA's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 22:35
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Elicio Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert BurnsH.C. Wainwright & Co.
Soumit RoyJonesTrading Institutional Services, LLC
Matthew BieglerOppenheimer & Co. Inc.